

## Understanding of Problem Statement

The problem focuses on how a pharmaceutical company can strategically improve its **tier level** to make its medicines more affordable for patients while simultaneously boosting its sales and market share. In many healthcare reimbursement systems, drugs are categorized into tiers that determine how much of the cost is covered by insurance or government programs and how much is paid out of pocket by consumers. A higher tier often means that the medicine is either non-essential or more expensive, leading to higher patient costs and potentially lower demand. Conversely, moving a drug to a more favourable tier—where the government or insurers bear a larger percentage of the cost—reduces the financial burden on patients and can drive higher prescription rates and sales volume for the company.

Improving the tier level typically depends on a range of factors such as clinical effectiveness, cost-efficiency, safety profile, and comparative advantage over alternatives. The pharmaceutical company's challenge lies in demonstrating the value of its product through data-driven evidence, pricing strategies, and strong partnerships with regulatory and reimbursement authorities. By optimizing these aspects, the company can achieve better formulary placement, increase patient access, and improve both affordability and profitability in the long term.

## Resources Needed

- **Basic Drugs Formulary File** for drug coverage mapping.
- **Excluded Drugs Formulary File** to identify non-covered drugs per plan.
- **Plan Information File** containing CONTRACT\_ID, PLAN\_ID, region codes, and benefit details.
- **Prescribers by Geography/Drug file** for utilization and prescribing trend analysis.
- **Geography-level summary tables** with regional and seasonal aggregation definitions.
- **RxNorm mapping tables** to unify brand/generic names with RxCUI/NDC references.
- **Cost files** detailing Tot\_Drug\_Cst, LIS and Non-LIS cost shares.
- **Prescribers summary tables** for claim volumes and beneficiary counts.
- **Drug class and flags file** (e.g., Opioid\_Drug\_Flag, Antbtcc\_Drug\_Flag).
- **Geographic Locator file** for mapping PDP\_REGION\_CODE and MA\_REGION\_CODE.
- **Pharmacy Network File** with pharmacy IDs, retail/mail indicators, and service areas.
- **Plan deductibles and premiums data** for patient financial impact assessment.

## Features

### Formulary and Coverage Mapping

**Files:** “Basic Drugs Formulary File,” “Plan Information File,” “Excluded Drugs Formulary File”.

- **Columns:** FORMULARY\_ID, CONTRACT\_ID, PLAN\_ID, RXCUI, NDC, TIER\_LEVEL\_VALUE, PRIOR\_AUTHORIZATION\_YN, STEP\_THERAPY\_YN, QUANTITY\_LIMIT\_YN.
- **Use:** Map each RxCUI/NDC to its covered status, tier, and restrictions per plan, revealing formulary access and hurdles.

### Prescribing Behavior and Utilization Trends

**Files:** Prescribers by Geography/Drug, Geography-level summary tables (PDF definitions), RxNorm mapping tables.

- **Columns:** Brand/Generic name, Tot\_Prscrbrs, Tot\_Clms, Tot30\_Day\_Fills, Tot\_Drug\_Cst, Tot\_Benes.
- **Use:** Aggregate counts to reveal top drugs, prescription volumes, seasonal/geographic trends, and brand/generic adoption over time.

### Cost, Reimbursement, and Patient Burden Analysis

**Files:** Prescribers summary tables, Cost files, Plan Info & Formulary tiers.

- **Columns:** Tot\_Drug\_Cst, LIS\_Bene\_Cst\_Shr, NonLIS\_Bene\_Cst\_Shr, TIER\_LEVEL\_VALUE, CONTRACT\_ID, PLAN\_ID.
- **Use:** Calculate average cost per claim, plan-specific costs, LIS support, and out-of-pocket burden separation. Cross-reference with plan deductibles and premiums for full patient impact.

### Competitive Market Share Analysis (Brand vs. Generic)

**Files:** RxNorm tables, Prescriber summary tables, Formulary files.

- **Columns:** Brand Name, Generic Name, Tot\_Clms, RXCUI/NDC mapping.

- **Use:** Compare claim volume trajectories for brands vs. generics in the same therapeutic class, or correlate formulary position/tier to market share erosion/acquisition.

#### Opioid and Special Drug Class Surveillance

**Files:** Prescriber geography/drug file, drug flags.

- **Columns:** Opioid\_Drug\_Flag, Antbtcc\_Drug\_Flag, Antpsyct\_Drug\_Flag, Tot\_Clms, Tot\_Benes, Geography code.
- **Use:** Quantify aggregate claims, prescribers, and trends for opioids and controlled/specialty classes, flag regional or plan anomalies and regulatory risks.

#### Plan and Region Optimization

**Files:** Plan Info, Geographic Locator, Cost, Formulary.

- **Columns:** PDP\_REGION\_CODE, MA\_REGION\_CODE, PLAN\_NAME, TIER\_LEVEL\_VALUE, COST\_AMT\_PREF/NONPREF/MAIL\_PREF, Deductible, Premium.
- **Use:** Assess which plans and regions offer the most favorable (lowest cost, highest tier) access for target drugs; identify opportunities for improved contracting or direct-to-patient support initiatives.

#### Access and Network Reach

**Files:** Pharmacy Network File, Plan Information File.

- **Columns:** CONTRACT\_ID, PLAN\_ID, PHARMACY\_NUMBER, RETAIL/MAIL indicator, SERVICE AREA.
- **Use:** Analyze physical and mail pharmacist accessibility per plan/region, aiming to expand reach or target pharmacy relationships.

## Benefits of Individual Features

- **Formulary Coverage Mapping:** Enables precise understanding of which drugs are covered under each plan, their tier placement, and any utilization restrictions such as prior authorization or step therapy. This helps stakeholders identify potential barriers to patient access and tailor strategies accordingly.
- **Prescribing Behavior and Utilization Trends:** Aggregates prescriber and geographic data to reveal high-demand drugs, seasonal prescribing patterns, and regional differences. This insight aids in resource allocation, marketing strategies, and identification of changing drug adoption trends.
- **Cost, Reimbursement, and Patient Burden Analysis:** Provides detailed insights into the cost-effectiveness of drug therapies, patient out-of-pocket expenses including LIS and non-LIS burdens, and plan-specific reimbursement dynamics. This helps in designing more affordable plans and understanding financial barriers affecting medication adherence.
- **Competitive Market Share Analysis:** Compares brand versus generic drug utilization within therapeutic classes, linking formulary position to market share shifts. This feature supports competitive intelligence and guides formulary negotiations to maximize market penetration.
- **Opioid and Special Drug Class Surveillance:** Tracks utilization patterns and prescriber behavior for controlled and specialty drugs, flagging potential regulatory risks or regional prescribing anomalies. This is critical for compliance monitoring and targeted intervention efforts.
- **Plan and Region Optimization:** Assesses which plans and geographic regions offer the most favorable drug access and cost conditions. This facilitates targeted contracting, optimized plan design, and directs patient support initiatives where needed the most.
- **Access and Network Reach:** Evaluates physical and mail-order pharmacy availability for each plan and region. Improved network insights support expansion strategies and enhanced patient convenience in medication access.